Targeting metabolic reprogramming to overcome drug resistance in advanced bladder cancer: insights from gemcitabine‐ and cisplatin‐resistant models
Molecular Oncology · 2024
DOI: 10.1002/1878-0261.13684 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Oncology, 2024. Verfasst von Ichiro Kawahara und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Graduate School of Medical and Dental Sciences, Kagoshima University, Japan. Hauptthemen laut MEDLINE: Urinary Bladder Neoplasms, Cisplatin, Gemcitabine, Deoxycytidine. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Society for the Promotion of Science.
Abstract (Originalsprache)
Gemcitabine plus cisplatin (GC) combination chemotherapy is the primary treatment for advanced bladder cancer (BC) with unresectable or metastatic disease. However, most cases develop resistance to this therapy. We investigated whether drug resistance could be targeted through metabolic reprogramming therapies. Metabolomics analyses in our lab's gemcitabine‐ and cisplatin‐resistant cell lines revealed increased phosphoglycerate dehydrogenase ( PHGDH ) expression in gemcitabine‐resistant cells compared with parental cells. Isocitrate dehydrogenase 2 (IDH2) gain of function stabilized hypoxia‐inducible factor1α ( HIF1α ) expression, stimulating aerobic glycolysis. In gemcitabine‐resistant cells, elevated fumaric acid suppressed prolyl hydroxylase domain‐containing protein 2/Egl nine homolog 1 ( PHD2 ) and stabilized HIF1α expression. PHGDH downregulation or inhibition in gemcitabine‐resistant BC cells inhibited their proliferation, migration, and invasion. Cisplatin‐resistant cells showed elevated fatty acid metabolism, upregulating fatty acid synthase ( FASN ) downstream of tyrosine kinase. Using the fibroblast growth factor receptor ( FGFR ) tyrosine kinase inhibitor erdafitinib, we inhibited malonyl‐CoA production, which is crucial for fatty acid synthesis, and thereby suppressed upregulated HIF1α expression. Combination treatment with NCT503 and erdafitinib synergistically suppressed tumor cell proliferation and induced apoptosis in vitro and in vivo . Understanding these mechanisms could enable innovative BC therapeutic strategies to be developed.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Graduate School of Medical and Dental Sciences, Kagoshima University, Japan.
ORCID-Profile: Hirofumi Yoshino, Hideki Enokida
Förderung
- Japan Society for the Promotion of Science
Zitieren
APA
Kawahara, I., Yoshino, H., Fukumoto, W., Arima, J., Saito, S., Li, G., Fukuda, I., Mitsuke, A., Sakaguchi, T., Inoguchi, S., Matsushita, R., Nakagawa, M., Tatarano, S., Yamada, Y., & Enokida, H. (2024). Targeting metabolic reprogramming to overcome drug resistance in advanced bladder cancer: insights from gemcitabine‐ and cisplatin‐resistant models. Molecular Oncology. https://doi.org/10.1002/1878-0261.13684
Vancouver
Kawahara I, Yoshino H, Fukumoto W, Arima J, Saito S, Li G, et al. Targeting metabolic reprogramming to overcome drug resistance in advanced bladder cancer: insights from gemcitabine‐ and cisplatin‐resistant models. Molecular Oncology. 2024. doi:10.1002/1878-0261.13684
BibTeX
@article{Kawahara2024,
author = {Kawahara, Ichiro and Yoshino, Hirofumi and Fukumoto, Wataru and Arima, Junya and Saito, Saeki and Li, Gang and Fukuda, Ikumi and Mitsuke, Akihiko and Sakaguchi, Takashi and Inoguchi, Satoru and Matsushita, Ryosuke and Nakagawa, Masayuki and Tatarano, Shuichi and Yamada, Yasutoshi and Enokida, Hideki},
title = {Targeting metabolic reprogramming to overcome drug resistance in advanced bladder cancer: insights from gemcitabine‐ and cisplatin‐resistant models},
journal = {Molecular Oncology},
year = {2024},
doi = {10.1002/1878-0261.13684}
}
EUVIMED